Clinical trial Recruiting at 1 site Observational Ages 7 and up

Diagnosing abdominal pain with a six-RNA blood test

Official title: Neutrophil Activation Test Using RNA Levels to Assist in the Diagnosis of Abdominal Pain: The NATURAL Study

Run by True Bearing Diagnostics, Inc. · NCT07579312 · Data updated 2026-11-12

This study will test whether a blood test that measures six RNA markers can help doctors determine if abdominal pain in people aged 7 and older is caused by infections such as appendicitis, diverticulitis, or pyelonephritis.

Quick facts

Study typeObservational
Ages7 Years and up
SexAll
Enrollment1000 (estimated)
SponsorTrue Bearing Diagnostics, Inc.
Industry-sponsored
Drugs / interventionsprednisone
Locations1 site (Washington D.C., District of Columbia)
StatusRecruiting
StartedApril 17, 2026
Main results expectedApril 2027
Study endsSeptember 2027
Registry record updatedMay 12, 2026
Trial IDNCT07579312 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

People older than 7 years with non-traumatic abdominal pain who are suspected of having an intra-abdominal infection and for whom CT, ultrasound, endoscopy, or surgery may be considered are ideal candidates.

Probably not a fit

Patients who are hemodynamically unstable, unable to provide consent or assent, involuntary detainees (e.g., prisoners), or whose pain is clearly traumatic or noninfectious are unlikely to benefit from this observational diagnostic test.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The NATURAL Study is a prospective, pragmatic observational project sponsored by True Bearing Diagnostics and planned at five or more academic centers, including Children's National Hospital. Investigators will collect stabilized whole-blood samples for the TruNAV six-RNA biomarker panel from patients presenting with suspected intra-abdominal infections while participants receive standard clinical evaluation and imaging. RNA results will be compared to clinical diagnoses, imaging, and operative findings to calculate sensitivity, specificity, and predictive values, with a target of ~90% sensitivity and >90% negative predictive value. The protocol is minimal-risk and involves venipuncture and routine data collection without changing clinical care.

Why it matters

Potential benefit: If successful, the test could quickly rule in or rule out abdominal infections, potentially reducing unnecessary imaging and speeding appropriate treatment.

How similar studies have gone: Host-response RNA panels have shown promise for diagnosing infections in sepsis and respiratory illnesses, but applying a six-RNA panel specifically to intra-abdominal infections is a relatively novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Age \> 7 yr old Abdominal pain of likely non-traumatic origin Risk of intra-abdominal infection (see IAI signs) Ability to provide informed consent/assent Potential to order abdominal CT, ultrasound, endoscopy, or surgery for possible IAI

Exclusion Criteria:

Any situation where delay could be detrimental Hemodynamically unstable (see age-adjusted criteria) Prisoner or other involuntary detainee Inability to provide informed consent/assent

Where it's running

  • Children's National Hospital
    Washington D.C., District of Columbia, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.